Use of NF-kB Inhibition in Combination Therapy for Cancer
First Claim
Patent Images
1. A method of enhancing the cytotoxic effects of an antineoplastic chemotherapeutic agent, comprising administering to a mammalian subject in need of said antineoplastic chemotherapeutic agent a therapeutically effective amount of NF-κ
- B inhibitor in conjunction with the administration of the chemotherapeutic agent, whereby the cytotoxic effect of said radiation therapy is increased compared to that which would occur in the absence of NF-κ
B inhibitor.
2 Assignments
0 Petitions
Accused Products
Abstract
The use of NF-κB inhibitors to enhance the cytotoxic effects of chemotherapy or radiation therapy in the treatment of neoplastic conditions is described.
-
Citations
17 Claims
-
1. A method of enhancing the cytotoxic effects of an antineoplastic chemotherapeutic agent, comprising administering to a mammalian subject in need of said antineoplastic chemotherapeutic agent a therapeutically effective amount of NF-κ
- B inhibitor in conjunction with the administration of the chemotherapeutic agent, whereby the cytotoxic effect of said radiation therapy is increased compared to that which would occur in the absence of NF-κ
B inhibitor. - View Dependent Claims (2, 3, 14, 16)
- B inhibitor in conjunction with the administration of the chemotherapeutic agent, whereby the cytotoxic effect of said radiation therapy is increased compared to that which would occur in the absence of NF-κ
-
4-5. -5. (canceled)
-
6. A method of enhancing chemotherapeutic cytotoxicity in a mammalian subject treated with an antineoplastic chemotherapeutic agent, comprising administering to the mammalian subject a therapeutically effective amount of NF-κ
- B inhibitor in conjunction with the administration of the chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur in the absence of NF-κ
B inhibitor. - View Dependent Claims (7, 8, 15, 17)
- B inhibitor in conjunction with the administration of the chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased compared to that which would occur in the absence of NF-κ
-
9-13. -13. (canceled)
Specification